- Home
- HOWL vs SNAL Comparison
HOWL vs SNAL Comparison
Compare HOWL & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- SNAL
- Stock Information
- Founded
- HOWL 2017
- SNAL 2000
- Country
- HOWL United States
- SNAL United States
- Employees
- HOWL N/A
- SNAL N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- SNAL Computer Software: Prepackaged Software
- Sector
- HOWL Health Care
- SNAL Technology
- Exchange
- HOWL Nasdaq
- SNAL Nasdaq
- Market Cap
- HOWL 87.4M
- SNAL 92.8M
- IPO Year
- HOWL 2021
- SNAL 2022
- Fundamental
- Price
- HOWL $1.49
- SNAL $2.72
- Analyst Decision
- HOWL Strong Buy
- SNAL
- Analyst Count
- HOWL 2
- SNAL 0
- Target Price
- HOWL $9.50
- SNAL N/A
- AVG Volume (30 Days)
- HOWL 260.9K
- SNAL 143.4K
- Earning Date
- HOWL 03-06-2025
- SNAL 03-31-2025
- Dividend Yield
- HOWL N/A
- SNAL N/A
- EPS Growth
- HOWL N/A
- SNAL N/A
- EPS
- HOWL N/A
- SNAL 0.08
- Revenue
- HOWL $3,386,000.00
- SNAL $86,822,973.00
- Revenue This Year
- HOWL N/A
- SNAL $39.43
- Revenue Next Year
- HOWL $34.17
- SNAL $26.12
- P/E Ratio
- HOWL N/A
- SNAL $35.99
- Revenue Growth
- HOWL N/A
- SNAL 82.23
- 52 Week Low
- HOWL $1.26
- SNAL $0.52
- 52 Week High
- HOWL $8.19
- SNAL $3.42
- Technical
- Relative Strength Index (RSI)
- HOWL 54.09
- SNAL 57.64
- Support Level
- HOWL $1.28
- SNAL $2.61
- Resistance Level
- HOWL $1.60
- SNAL $3.42
- Average True Range (ATR)
- HOWL 0.10
- SNAL 0.34
- MACD
- HOWL 0.03
- SNAL 0.03
- Stochastic Oscillator
- HOWL 67.65
- SNAL 60.92
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.